Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

Introduction: Superior vena cava syndrome is described as the obstruction of blood flow through the superior vena cava. The literature reports that the incidence of this pathology varies from 1 case in every 650 inhabitants and 1 case in every 3 100 inhabitants. Since this condition is very rare in...

Full description

Saved in:
Bibliographic Details
Main Authors: Ángela Milena Díaz-Díaz, María Alejandra Ardila-Gutiérrez, Catalina Cáceres-Ramírez, Santiago Zuluaga-Salazar, María Fernanda Zuluaga-Amaya, Melquisedec Galvis-Méndez
Format: Article
Language:English
Published: Universidad Nacional de Colombia 2020-07-01
Series:Case Reports
Subjects:
Online Access:https://revistas.unal.edu.co/index.php/care/article/view/83526
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846152066437742592
author Ángela Milena Díaz-Díaz
María Alejandra Ardila-Gutiérrez
Catalina Cáceres-Ramírez
Santiago Zuluaga-Salazar
María Fernanda Zuluaga-Amaya
Melquisedec Galvis-Méndez
author_facet Ángela Milena Díaz-Díaz
María Alejandra Ardila-Gutiérrez
Catalina Cáceres-Ramírez
Santiago Zuluaga-Salazar
María Fernanda Zuluaga-Amaya
Melquisedec Galvis-Méndez
author_sort Ángela Milena Díaz-Díaz
collection DOAJ
description Introduction: Superior vena cava syndrome is described as the obstruction of blood flow through the superior vena cava. The literature reports that the incidence of this pathology varies from 1 case in every 650 inhabitants and 1 case in every 3 100 inhabitants. Since this condition is very rare in the pediatric population, no clear figure has been reported regarding its incidence in children. The use of a central venous catheter in newborns is a risk factor for this condition, as it may cause a thrombus due to the inflammatory reaction against the device. Therefore, it is necessary to initiate anticoagulation management and remove the catheter. Case presentation: Premature male newborn, (31.4 weeks gestation), with acute respiratory distress syndrome, early neonatal sepsis, pneumonia, necrotizing enterocolitis on 2 occasions, intestinal obstruction due to adhesions and intestinal volvulus. At 90 days of age, he presented thrombosis of the superior vena cava without involvement of the jugular and subclavian vein junction in the right atrium. Anticoagulant management was started, but given his unfavorable evolution, a multidisciplinary medical board was held to assess the risks, benefits, and treatment options in this age group. It was decided to start intracavitary tissue plasminogen activator treatment associated with mechanical thrombectomy and angioplasty of the superior vena cava. Due to the difficulty of conducting clinical trials in this population and the rates of major bleeding complications obtained with thrombolytic therapies, there is very little information available on the use of tissue plasminogen activator in newborns. For this reason, alteplase is seldom considered as the therapy of choice. However, in patients with life-threatening thrombosis, such as the present case, the results obtained in adults could be extrapolated in search of a favorable outcome. Conclusions: Fibrinolytic therapy is a way to reduce the size of the thrombus, but it dramatically increases the risk of bleeding; consequently, these patients must be strictly monitored. In pediatric populations, due to the diameter of the blood vessels, thrombectomy is difficult to perform; additionally, recurrent thrombosis and the need for transfusion of blood products are frequent.
format Article
id doaj-art-925094ec70c84ddf91e4c0c985dfd0c8
institution Kabale University
issn 2462-8522
language English
publishDate 2020-07-01
publisher Universidad Nacional de Colombia
record_format Article
series Case Reports
spelling doaj-art-925094ec70c84ddf91e4c0c985dfd0c82024-11-26T23:59:03ZengUniversidad Nacional de ColombiaCase Reports2462-85222020-07-016210.15446/cr.v6n2.83526Fibrinolytic therapy in newborns with superior vena cava syndrome. Case reportÁngela Milena Díaz-Díaz0https://orcid.org/0000-0001-5675-255XMaría Alejandra Ardila-Gutiérrez1https://orcid.org/0000-0001-8853-6851Catalina Cáceres-Ramírez2https://orcid.org/0000-0002-5369-2579Santiago Zuluaga-Salazar3https://orcid.org/0000-0001-8222-3205María Fernanda Zuluaga-Amaya4https://orcid.org/0000-0002-4605-3592Melquisedec Galvis-Méndez5https://orcid.org/0000-0001-6238-9590Clínica FOSCAL - Pediatrics Specialty - Floridablanca - Colombia. Universidad Autónoma de Bucaramanga - Faculty of Medicine - Bucaramanga - ColombiaUniversidad Autónoma de Bucaramanga - Faculty of Medicine - Bucaramanga - ColombiaUniversidad Autónoma de Bucaramanga - Faculty of Medicine - Bucaramanga - ColombiaUniversidad Autónoma de Bucaramanga - Faculty of Medicine - Bucaramanga - ColombiaUniversidad Autónoma de Bucaramanga - Faculty of Medicine - Bucaramanga - ColombiaClínica FOSCAL - Radiology Specialty - Floridablanca - Colombia Introduction: Superior vena cava syndrome is described as the obstruction of blood flow through the superior vena cava. The literature reports that the incidence of this pathology varies from 1 case in every 650 inhabitants and 1 case in every 3 100 inhabitants. Since this condition is very rare in the pediatric population, no clear figure has been reported regarding its incidence in children. The use of a central venous catheter in newborns is a risk factor for this condition, as it may cause a thrombus due to the inflammatory reaction against the device. Therefore, it is necessary to initiate anticoagulation management and remove the catheter. Case presentation: Premature male newborn, (31.4 weeks gestation), with acute respiratory distress syndrome, early neonatal sepsis, pneumonia, necrotizing enterocolitis on 2 occasions, intestinal obstruction due to adhesions and intestinal volvulus. At 90 days of age, he presented thrombosis of the superior vena cava without involvement of the jugular and subclavian vein junction in the right atrium. Anticoagulant management was started, but given his unfavorable evolution, a multidisciplinary medical board was held to assess the risks, benefits, and treatment options in this age group. It was decided to start intracavitary tissue plasminogen activator treatment associated with mechanical thrombectomy and angioplasty of the superior vena cava. Due to the difficulty of conducting clinical trials in this population and the rates of major bleeding complications obtained with thrombolytic therapies, there is very little information available on the use of tissue plasminogen activator in newborns. For this reason, alteplase is seldom considered as the therapy of choice. However, in patients with life-threatening thrombosis, such as the present case, the results obtained in adults could be extrapolated in search of a favorable outcome. Conclusions: Fibrinolytic therapy is a way to reduce the size of the thrombus, but it dramatically increases the risk of bleeding; consequently, these patients must be strictly monitored. In pediatric populations, due to the diameter of the blood vessels, thrombectomy is difficult to perform; additionally, recurrent thrombosis and the need for transfusion of blood products are frequent. https://revistas.unal.edu.co/index.php/care/article/view/83526Premature InfantSuperior Vena CavaAlteplaseCatheterization Central Venous
spellingShingle Ángela Milena Díaz-Díaz
María Alejandra Ardila-Gutiérrez
Catalina Cáceres-Ramírez
Santiago Zuluaga-Salazar
María Fernanda Zuluaga-Amaya
Melquisedec Galvis-Méndez
Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
Case Reports
Premature Infant
Superior Vena Cava
Alteplase
Catheterization Central Venous
title Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
title_full Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
title_fullStr Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
title_full_unstemmed Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
title_short Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report
title_sort fibrinolytic therapy in newborns with superior vena cava syndrome case report
topic Premature Infant
Superior Vena Cava
Alteplase
Catheterization Central Venous
url https://revistas.unal.edu.co/index.php/care/article/view/83526
work_keys_str_mv AT angelamilenadiazdiaz fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport
AT mariaalejandraardilagutierrez fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport
AT catalinacaceresramirez fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport
AT santiagozuluagasalazar fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport
AT mariafernandazuluagaamaya fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport
AT melquisedecgalvismendez fibrinolytictherapyinnewbornswithsuperiorvenacavasyndromecasereport